This is the third report of the biological therapy element of the UK IBD audit and all analyses within this report include only those patients who were newly started on biological therapies between 12 September 2011 (start of data collection) and 28 February 2014.
- 160/80 mg of adalimumab should be used for induction therapy.
- Clinicians should consider stopping 5‐aminosalicylic acid (5‐ASA) drugs in patients on biologics with Crohn’s disease. Steroids should be weaned and stopped where possible.
- Sites should routinely assess disease activity at baseline and again at 3‐ and 12‐month follow‐up; this measure forms an important part of objective assessment of response to treatment and the quality of care provided by the IBD service.
- Local teams should encourage patients to complete patient‐reported outcome measures (EQ‐5D4 and CCQ12) at baseline and again at 3‐ and 12‐month follow‐up; this measure also forms an important part of objective assessment of response to treatment and the quality of care provided by the IBD service.
- Sites participating in the audit should export their own local data and use them for local analyses, benchmarking and quality improvement activities.
- The findings and recommendations of this report should be shared at relevant multidisciplinary and clinical governance / audit meetings, and local action plans for implementing change should be devised.
- Healthcare and Quality Improvement Partnership (HQIP)
- British Society of Gastroenterology
- Crohn's and Colitis UK
- British Society of Paediatric Gastroenterology, Heptology and Nutrition
- Royal College of Nursing
- British Dietetic Association
- Primary Care Society for Gastroenterology
- Association of Coloproctology of Great Britain and Ireland
- Royal Pharmaceutical Society